|
Degarelix Clinical Trials
8 actively recruiting trials across 8 locations
▼ -1 trial since August 2026
Also known as: ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486 +5 more
Pipeline
Phase 2: 5Phase 3: 2Phase 4: 1
Top Sponsors
- University of Colorado, Denver1
- SWOG Cancer Research Network1
- Mayo Clinic1
- M.D. Anderson Cancer Center1
- Jose Pablo Leone1
Indications
- Cancer7
- Stage IVB Prostate Cancer AJCC v83
- Biochemically Recurrent Prostate Carcinoma2
- Stage IVA Prostate Cancer AJCC v82
- Stage IV Prostate Cancer AJCC v82
Anchorage, Alaska1 trial
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Anchorage Associates in Radiation Medicine
Phase 3
Gilbert, Arizona1 trial
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Banner MD Anderson Cancer Center
Phase 3
Phoenix, Arizona1 trial
Duarte, California1 trial
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2
Aurora, Colorado1 trial
Cardiometabolic Consequences of the Loss of Ovarian Function
University of Colorado Anschutz Medical Campus
Phase 4
Washington D.C., District of Columbia1 trial
ETHAN - ET for Male BC
Georgetown University Medical Center
Phase 2
Miami, Florida1 trial
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Miami Cancer Institute at Baptist Health, Inc.
Phase 2
Houston, Texas1 trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M D Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.